Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus NYSTEX.
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death. At high concentrations, it may also directly damage fungal membranes.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
200 mg IV loading dose, then 100-200 mg IV once daily; for invasive candidiasis, 800 mg IV loading dose then 400 mg IV once daily.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function; prolonged to 98 hours in end-stage renal disease, requiring dose adjustment.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 11% is excreted as metabolites in urine; fecal excretion accounts for less than 5%.
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal